Gilead Sciences, Inc.
GILD
Market Cap$82.37B
Close$
Earnings Call Q4 2023
February 6, 2024 - AI Summary
Gilead Sciences reported strong full-year and fourth quarter performance in 2023, with 7% growth in product sales (excluding Veklury) driven by HIV and Oncology.
HIV sales grew by almost $1 billion, with Biktarvy sales increasing 14% to nearly $12 billion and gaining market share in the US.
Oncology sales grew 37% to almost $3 billion, driven by Kite cell therapies and Trodelvy.
Exclusive for Stockcircle Pro members
Sign up
$73.81
10.1% upside
Current Fair Value
10.1% upsideUndervalued by 10.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $82.37 Billion |
|---|---|
| Enterprise Value | $100.10 Billion |
| Dividend Yield | $2.9343 (4.44%) |
| Earnings per Share | $4.5 |
| Beta | 0.49 |
| Outstanding Shares | 1,245,077,219 |
| Avg 30 Day Volume | 6,250,279 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.54 |
|---|---|
| PEG | -113.04 |
| Price to Sales | 3.19 |
| Price to Book Ratio | 3.72 |
| Enterprise Value to Revenue | 3.69 |
| Enterprise Value to EBIT | 11.36 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 1.09 |
Revenue Sources
No data
ESG Score
No data
About Gilead Sciences, Inc.
CEO: Daniel O'Day